Opinion|Videos|March 6, 2025
The PEACE-3 Trial
Panelists discuss how the PEACE-3 trial demonstrated meaningful clinical benefits with the combination of radium-223 and enzalutamide compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), showing both improved radiologic progression-free survival and a significant overall survival advantage of 7.3 months.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The PEACE-3 trial investigated whether the combination of radium-223 and enzalutamide (RAD-ENZ) improves cancer progression over enzalutamide alone in patients with mCRPC.
- Please discuss the significance of a 31% reduction in radiologic disease progression or death with the combination of RAD-ENZ.
- Discussing the secondary end point in a bit more detail, the overall survival, from 35 to 42.3 months, was statistically significant. What does this mean in clinical practice?
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Initial prostate cancer presentation, family history linked to survival in mCRPC
2
State of Men’s Health Act: What urologists need to know
3
FDA greenlights phase 1 trial of ADI-212 in mCRPC
4
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
5